PHE News

Philipson in Forbes: "Give Tax Payers A Rebate for Medical Innovation?"

In his latest commentary for Forbes.com, Tomas Philipson examines tax-funded medical research and its market value.

READ MORE

PHE’s Goldman, Lakdawalla, and Philipson To Participate in BIO Panel

Precision Health Economics’ (PHE) Dana Goldman, Darius Lakdawalla, and Tomas Philipson will be featured in the BIO International Convention panel - The Future of Biosimilars: How Will Policy and Market Dynamics Impact Patient Value and Access in the US?

READ MORE

Lakdawalla in AP's The Big Story: "Why Aren't You Shopping for Lower Prescription Drug Prices?"

Precision Health Economics founder and Chief Strategy Officer Darius Lakdawalla discusses pharmacy pricing and apps with Matthew Perrone.

READ MORE

Precision's Renick in The Pink Sheet: Will Data Be Enough to Support a New Drug That Battles COPD?  

In a recent article in The Pink Sheet, Precision’s Dan Renick weighs in on the importance of data to understand the potential impact of new, innovative drugs.

READ MORE

Precision Researchers Prominently Featured in AJMC's Special Issue on HCV

Precision Health Economics authors are prominently featured in the May 2016, Special Issue on the Hepatitis C virus, just released by The American Journal of Managed Care.

READ MORE
 
  • Academic Insights at

    the Speed of Business

     
  • Intellectual Integrity

    Led by professors at elite research universities, we bring intellectual integrity, academic rigor, and a creative approach to the most challenging problems in heath care.

     
  • Real World Impact

    PHE recommendations have defined and changed national and international payment policies.

     
  • Unparalleled Influence

    We frequently appear in top-tier publications and media outlets-- our work reaches top decision makers and influences outcomes.

     
  • Evidence Generation and

    Commercial Excellence

    As part of Precision for Value, our academic approach to research can be linked with a tailored, commercial approach that demonstrates the value of innovative medications.

     
  • Academic Insights at

    the Speed of Business